Galanin in Alzheimer disease.
Document Type
Article
Abstract
Galanin (GAL) and GAL receptors (GALR) are overexpressed in limbic brain regions associated with cognition in Alzheimer disease (AD). The functional consequences of this overexpression are unclear. Because GAL inhibits cholinergic transmission and restricts long-term potentiation in the hippocampus, GAL overexpression may exacerbate clinical features of AD. In contrast, GAL expression increases in response to neuronal injury, and galaninergic hyperinnervation prevents the decreased production of protein phosphatase 1 subtype mRNAs in cholinergic basal forebrain neurons in AD. Thus, GAL may also be neuroprotective for AD. Further elucidation of GAL activity in selectively vulnerable brain regions will help gauge the therapeutic potential of GALR ligands for the treatment of AD.
Publication Date
1-1-2003
Publication Title
Molecular interventions
ISSN
15340384
Volume
3
Issue
3
First Page
137
Last Page
156
PubMed ID
14993421
Digital Object Identifier (DOI)
10.1124/mi.3.3.137
Recommended Citation
Counts, Scott E.; Perez, Sylvia E.; Ginsberg, Stephen D.; De Lacalle, Sonsoles; and Mufson, Elliott J., "Galanin in Alzheimer disease." (2003). Translational Neuroscience. 1626.
https://scholar.barrowneuro.org/neurobiology/1626